SCHEMBL469376

SCHEMBL469376

CCCCC(CC)COC(=O)/C(C#N)=C(\c1ccccc1)c1ccc(OC)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.86
LMNA P02545 3/20 0.86
MAPK1 P28482 2/20 0.86
TDP1 Q9NUW8 2/20 0.50
CYP3A4 P08684 3/20 0.47
CA2 P00918 1/20 0.47
TSHR P16473 3/20 0.43
HSD17B10 Q99714 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43
PTGS2 P35354 2/20 0.41
CYP19A1 P11511 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
ATM Q13315 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16762811 1.00 ALDH1A1 (0.86) ALDH1A1LMNAMAPK1TDP1CYP3A4
SCHEMBL346933 1.00 ALDH1A1 (0.86) ALDH1A1LMNAMAPK1TDP1CYP3A4
SCHEMBL21908164 1.00 ALDH1A1 (0.86) ALDH1A1LMNAMAPK1TDP1CYP3A4
SCHEMBL10067446 0.93 ALDH1A1 (0.74) ALDH1A1LMNAMAPK1TDP1CYP3A4
Octocrylene SCHEMBL16483 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TDP1CYP3A4
Octocrylene SCHEMBL1769135 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TDP1CYP3A4
SCHEMBL15492965 0.92 ALDH1A1 (0.72) ALDH1A1LMNAMAPK1TDP1CYP3A4
Octocrylene SCHEMBL28123035 0.92 ALDH1A1 (0.98) ALDH1A1LMNAMAPK1TDP1CYP3A4
Octocrylene SCHEMBL19583477 0.91 ALDH1A1 (0.95) ALDH1A1LMNAMAPK1TDP1CYP3A4
Octocrylene SCHEMBL21835135 0.90 ALDH1A1 (0.69) ALDH1A1LMNAMAPK1TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative L'ORÉAL (FR) 2025-10-28 US claimed
EP-4392144-A1 SUNSCREEN COMPOSITION COMPRISING: A METAL OXIDE, SPF ACTIVE INGREDIENT; AND ONE OR MORE SPF ENHANCEMENT COMPONENT COMPRISING A PHOTOSTABILIZER, AN ANTIOXIDANT, OR A COMBINATION THEREOF Colgate-Palmolive Company (US) 2024-07-03 EP claimed
WO-2023224944-A1 SUNSCREEN COMPOSITION COMPRISING: A METAL OXIDE, SPF ACTIVE INGREDIENT; AND ONE OR MORE SPF ENHANCEMENT COMPONENT COMPRISING A PHOTOSTABILIZER, AN ANTIOXIDANT, OR A COMBINATION THEREOF COLGATE-PALMOLIVE COMPANY (US) 2023-11-23 WO claimed
US-20230364005-A1 Sunscreen Compositions and Methods of Use COLGATE-PALMOLIVE COMPANY (US) 2023-11-16 US claimed
US-20230044544-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2023-02-09 US claimed
EP-4076677-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2022-10-26 EP claimed
US-20260115122-A1 PERSONAL CARE COMPOSITIONS COMPRISING PANCRATIUM MARITIMUM Galderma Holding SA (CH) 2026-04-30 US disclosed
US-12605316-B2 Alkenone-based formulations for topical applications WOODS HOLE OCEANOGRAPHIC INSTITUTION (US) 2026-04-21 US disclosed
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative L'ORÉAL (FR) 2025-10-28 US disclosed
US-20250152486-A1 Personal Care Compositions and Methods of Using Same COLGATE-PALMOLIVE COMPANY (US) 2025-05-15 US disclosed
EP-4547340-A1 PERSONAL CARE COMPOSITIONS COMPRISING PANCRATIUM MARITIMUM Galderma Holding SA (CH) 2025-05-07 EP disclosed
WO-2025072942-A1 PERSONAL CARE COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2025-04-03 WO disclosed
US-20250107983-A1 Personal Care Compositions COLGATE-PALMOLIVE COMPANY (US) 2025-04-03 US disclosed
US-7754191-B2 Method of quenching electronic excitation of chromophore-containing organic molecules photoactive compositions HALLSTAR INNOVATIONS CORP. (US) 2010-07-13 US disclosed
US-7754191-B2 Method of quenching electronic excitation of chromophore-containing organic molecules photoactive compositions HALLSTAR INNOVATIONS CORP. (US) 2010-07-13 US disclosed
WO-2010051103-A1 METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHOTOACTIVE COMPOSITIONS HALLSTAR INNOVATIONS CORP. (US) 2010-05-06 WO disclosed
US-20090324570-A1 Photostabilization of Retinoids with Alkoxycrylene Compounds HALLSTAR INNOVATIONS CORP. (US) 2009-12-31 US disclosed
US-20090324570-A1 Photostabilization of Retinoids with Alkoxycrylene Compounds HALLSTAR INNOVATIONS CORP. (US) 2009-12-31 US disclosed
US-20090057627-A1 Method of quenching electronic excitation of chromophore-containing organic molecules photoactive compositions HALLSTAR INNOVATIONS CORP. (US) 2009-03-05 US disclosed
US-20090057627-A1 Method of quenching electronic excitation of chromophore-containing organic molecules photoactive compositions HALLSTAR INNOVATIONS CORP. (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044544-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE HAAO, HAO2, HPD ALDH1A1 103/4885LMNA 1578/4885MAPK1 3298/4885
US-12605316-B2 Alkenone-based formulations for topical applications CUTA, FLNA, TELO2 ALDH1A1 986/4885LMNA 1103/4885MAPK1 3436/4885
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative HAAO, HPD, P4HA1 ALDH1A1 127/4885LMNA 1508/4885MAPK1 3213/4885
US-20260115122-A1 PERSONAL CARE COMPOSITIONS COMPRISING PANCRATIUM MARITIMUM B3GNT2, GLA, AMPD2 ALDH1A1 868/4885LMNA 2668/4885MAPK1 568/4885
US-20090324570-A1 Photostabilization of Retinoids with Alkoxycrylene Compounds RBP4, RARA, RBP1 ALDH1A1 60/4885LMNA 408/4885MAPK1 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.